BCRX
BioCryst Pharmaceuticals Inc+0.27 (+3.10%) TodayNov 4, 10:43 AM ET
About BCRX
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Company
- Headquarters
- Durham, NC
- Employees
- 435 (2026)
- Listed
- Mar 3, 1994
- Exchange
- Nasdaq
- Website
- biocryst.com
- SEC industry
- Biological Products, (no Diagnostic Substances)
- Cylvex sector
- Health Care · Biotech
Biotech
- Market cap #30 of 146
- P/B #121 of 131
Ranked highest first among stocks Cylvex covers.
- AMGNAmgen Inc$253.3B+1.56%
- GILDGilead Sciences Inc$211.8B+1.94%
- MRNAModerna Inc$99.18B+8.75%
- ARGXargenx SE$57.12B+0.80%
- RVMDRevolution Medicines, Inc.$42.27B+1.54%
Financial summary
Related companies
About
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
From company filings and market data · Not investment advice
Price data
From daily bars
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.